DexCom, Inc. $DXCM Shares Purchased by Glenmede Trust Co. NA

Glenmede Trust Co. NA boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 394,751 shares of the medical device company’s stock after purchasing an additional 105,928 shares during the period. Glenmede Trust Co. NA’s holdings in DexCom were worth $24,790,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Reflection Asset Management acquired a new stake in shares of DexCom during the 4th quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new stake in shares of DexCom during the 1st quarter valued at approximately $25,000. MCF Advisors LLC acquired a new position in DexCom in the fourth quarter valued at approximately $32,000. Wellington Grp LLC lifted its holdings in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 475 shares during the last quarter. Finally, DV Equities LLC purchased a new position in DexCom in the fourth quarter worth approximately $36,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

DexCom Stock Performance

NASDAQ:DXCM opened at $83.45 on Friday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $87.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The company has a 50 day moving average price of $73.14 and a 200 day moving average price of $69.20. The stock has a market capitalization of $32.20 billion, a P/E ratio of 32.98, a PEG ratio of 1.37 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.34% and a net margin of 20.12%.The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the previous year, the company earned $0.48 earnings per share. The firm’s quarterly revenue was up 13.1% compared to the same quarter last year. Equities research analysts forecast that DexCom, Inc. will post 2.6 EPS for the current year.

Insiders Place Their Bets

In related news, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 98,506 shares of company stock valued at $7,205,258. Insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent analyst reports. Mizuho raised their target price on DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday. Sanford C. Bernstein set a $77.00 price target on DexCom in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target for the company. Truist Financial set a $93.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $88.12.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.